Action S.Y. Bancorp - SYI

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE

MONTVALE, N.J., Feb. 24 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that it has entered into...

Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update

MONTVALE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that, following a review...

Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium

MONTVALE, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has completed enrollment of its...

Synvista Notified by NYSE Alternext of Continued Listing Standards Non-Compliance

Company Expects Its Common Stock to Remain Listed While it Engages in Compliance Process MONTVALE, N.J., Dec. 24 /PRNewswire-FirstCall/...

Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline

Synvista Therapeutics Technology Provided CML Biomarker Data for Studies MONTVALE, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Synvista...

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis

MONTVALE, N.J., Dec. 15 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has dosed the first patient in a...

Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit

MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX:SYI) today announced that it has submitted, and that the FDA...

Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA M

New Data Presented at the Meeting Demonstrate Vitamin E May Help Prevent Cardiovascular Events in Hp2-2 Diabetes MONTVALE, N.J., Nov. 11...

Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

- Presentation to be Webcast - MONTVALE, N.J. , Nov. 10 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX:SYI) announced today that...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

SYI - Frequently Asked Questions (FAQ)

What is the current S.Y. Bancorp share price?

The current share price of S.Y. Bancorp is US$ 0,00

What is the 1 year trading range for S.Y. Bancorp share price?

S.Y. Bancorp has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ROBNT Rex 2X Long HOOD Daily Target ETF	US$ 35,85 (30,89%)	8,38k
EFSH1847 Holdings LLC	US$ 0,2212 (18,29%)	70,96k
EPEmpire Petroleum Corporation	US$ 6,49 (16,94%)	1
VENUVenu Holding Corporation	US$ 10,99 (13,30%)	10
BGIBirks Group Inc	US$ 1,17 (9,35%)	101
SVTServotronics Inc	US$ 8,31 (-24,11%)	21
SLSRSolaris Resources Inc	US$ 3,30 (-18,11%)	201
BURUNuburu Inc	US$ 0,2146 (-14,50%)	48,2k
ATMPiPath Select MLP ETN	US$ 26,01 (-13,67%)	10
LGLLGL Group Inc	US$ 5,72 (-12,00%)	6
SOXSDirexion Daily Semiconductor Bear 3X Shares New	US$ 20,135 (0,52%)	947,98k
ETHU2x Ether ETF	US$ 4,38 (0,46%)	859,79k
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 27,36 (-0,65%)	772,79k
TSLZT Rex 2X Inverse Tesla Daily Target ETF	US$ 3,08 (-4,35%)	628,29k
MSTUT Rex 2X Long MSTR Daily Target ETF	US$ 8,55 (-0,81%)	337,62k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Synvista Therapeutics, (SYI)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

SYI Dernières nouvelles

Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE

Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update

Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium

Synvista Notified by NYSE Alternext of Continued Listing Standards Non-Compliance

Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis

Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit

Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA M

Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

SYI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Synvista Therapeutics, (SYI) Cours

Synvista Therapeutics, (SYI)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

SYI Dernières nouvelles

Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE

Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update

Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium

Synvista Notified by NYSE Alternext of Continued Listing Standards Non-Compliance

Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline

Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis

Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit

Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA M

Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

SYI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE